Revised SPCs: Braftovi (encorafenib) 50 mg and 75mg hard capsules

Various changes have been made to the SPC in line with its approval for use in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy.

Source:

electronic Medicines compendium